Sucampo Pharmaceuticals Inc. (SCMP)

18.00
0.00 (0.00)
Prev Close 18.00
Open 18.00
Day Low/High 17.95 / 18.07
52 Wk Low/High 9.30 / 18.75
Volume 956.24K
Avg Volume 2.73M
Exchange
Shares Outstanding 47.17M
Market Cap 849.04M
EPS 0.40
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Sucampo Pharmaceuticals, Inc. To Mallinckrodt Plc Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Sucampo Pharmaceuticals, Inc. To Mallinckrodt Plc Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Sucampo Pharmaceuticals, Inc.

SUCAMPO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale To Mallinckrodt Plc

SUCAMPO PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Investigates Sale To Mallinckrodt Plc

Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Sucampo Pharmaceuticals, Inc.

CORRECTING and REPLACING Investor Alert: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Sucampo Pharmaceuticals, Inc. to Mallinckrodt plc is Fair to Shareholders

CORRECTING and REPLACING Investor Alert: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Sucampo Pharmaceuticals, Inc. to Mallinckrodt plc is Fair to Shareholders

Third paragraph, first sentence of release should read: You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Sucampo to Mallinckrodt plc (NYSE:...

Try This Pair of Biotech Trades

Try This Pair of Biotech Trades

Teva and Mallinckrodt both lost over 50% of their value in 2017 and might catch some momentum here.

Interesting SCMP Put And Call Options For February 2018

Interesting SCMP Put And Call Options For February 2018

Investors in Sucampo Pharmaceuticals Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SCMP options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

SCMP: Insiders vs. Shorts

SCMP: Insiders vs. Shorts

The most recent short interest data was recently released for the 11/15/2017 settlement date, and Sucampo Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.06 "days to cover" versus the median component at 4.67. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Sucampo Pharmaceuticals Reaches Analyst Target Price

Sucampo Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Sucampo Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $15.50, changing hands for $15.60/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Insiders Were Right: SCMP Makes New 52-Week High

Insiders Were Right: SCMP Makes New 52-Week High

In trading on Thursday, shares of Sucampo Pharmaceuticals Inc touched a new 52-week high of $17.70/share. That's a 90.32% rise, or $8.4 per share from the 52-week low of $9.30 set back on 04/18/2017.

Sucampo To Host 2017 R&D Day On November 16 In New York

Sucampo To Host 2017 R&D Day On November 16 In New York

Event to be Webcast

SCMP: Insiders vs. Shorts

SCMP: Insiders vs. Shorts

The most recent short interest data was recently released for the 08/15/2017 settlement date, and Sucampo Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.14 "days to cover" versus the median component at 5.20. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Cancer Prevention Pharmaceuticals Receives $9.5 Million In Additional Funding From Sucampo Following Phase 3 Trial Progress

Cancer Prevention Pharmaceuticals Receives $9.5 Million In Additional Funding From Sucampo Following Phase 3 Trial Progress

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced it has received a total of $9.

First Week of October 20th Options Trading For Sucampo Pharmaceuticals (SCMP)

First Week of October 20th Options Trading For Sucampo Pharmaceuticals (SCMP)

Investors in Sucampo Pharmaceuticals Inc saw new options begin trading this week, for the October 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SCMP options chain for the new October 20th contracts and identified the following call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BETR, CG, DXCM, ITG, JLL, KEM, NUS, STRL, SUM, SWIR Downgrades: DVA, GHC, ISCA, QRVO, RDC, SCMP Initiations: ASPU Read on to get TheStreet Quant Ratings' detailed report: